Rituximab MedChemExpress (MCE)

Product Name	Rituximab
Synonyms	Rituxan Mabthera Rituximab Hsdb 7455 Mab thera Immunoglobulin G1 Ig gamma-1 chain C region Synonyms Rituxan Mabthera Rituximab Hsdb 7455 Mab thera Immunoglobulin G1 Ig gamma-1 chain C region IMMunoglobulin G1,anti-(huMan CD20 (antigen)) (huMan-Mouse Monoclonal IDEC-C2B8 g1-chain), disulfide withhuMan-Mouse Monoclonal IDEC-C2B8 k-chain, diMer Immunoglobulin G 1 (human-mouse monoclonal idec-C2B8 gamma1-chain anti-human antigen cd 20), disulfide with human-mouse monoclonal idec-C2B8 kappa-chain, dimer
CAS	174722-31-7
EINECS
Chemical Formula	C6416H9874N1688O1987S44
Molecular Weight
inchi
Package	1 mg;1 mg;5 mg;5 mg;10 mg;10 mg
Price	Email to quote
Descriptions	Rituximab Rituximab MedChemExpress (MCE) HY-P9913 174722-31-7 Anti-Human CD20 type I, Chimeric Antibody 98.53% Please store the product under the recommended conditions in the Certificate of Analysis. Shipping with dry ice. Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer. Rituximab inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab[1]. All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab induces high CDC killing of follicular lymphoma cells[2]. A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent[3]. C57BL/6 mice (8-10 wk of age) are inoculated 8×103 EL4-CD20+ cells in 200 μL of saline by tail vein injection. In parallel groups of mice, 150 g of rituximab, murine anti-CD20 IgG2a Ab 1F5, or control anti-human IL-2R Ab daclizumab in 300 μL of saline, or saline only is inoculated i.p. 24 h later[1]. A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent[3]. RDC Antibody Chimeric Human IgG1 kappa Human IgG1 kappa, Isotype Control \| \| \| \| \| \| \| \| \| \| [1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb Descriptions Rituximab Rituximab MedChemExpress (MCE) HY-P9913 174722-31-7 Anti-Human CD20 type I, Chimeric Antibody 98.53% Please store the product under the recommended conditions in the Certificate of Analysis. Shipping with dry ice. Rituximab is an anti-CD20 chimeric monoclonal antibody used for research of certain autoimmune diseases and cancer. Rituximab inhibits the proliferation of stimulated human B cells, which is associated with a relative increase of B cells with an activated naive phenotype. Aside from this population shift, there are no major changes in phenotype or cytokine profile of the various B-cell subsets. B cells stimulated in the presence of rituximab induces stronger T-cell proliferation, compared to B cells stimulated in the absence of rituximab[1]. All lymphoma cells tested are equally sensitive to antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-mediated phagocytosis of tumor cells, and rituximab-induced apoptosis. Rituximab induces high CDC killing of follicular lymphoma cells[2]. A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent[3]. C57BL/6 mice (8-10 wk of age) are inoculated 8×103 EL4-CD20+ cells in 200 μL of saline by tail vein injection. In parallel groups of mice, 150 g of rituximab, murine anti-CD20 IgG2a Ab 1F5, or control anti-human IL-2R Ab daclizumab in 300 μL of saline, or saline only is inoculated i.p. 24 h later[1]. A single injection of rituximab or the murine anti-CD20 Ab 1F5, given i.p. 1 day after the tumor, cures 100% of the animals. Depletion of either NK cells or neutrophils or both in tumor-injected animals does not affect the therapeutic activity of the drug. Similarly, rituximab is able to eradicate tumor cells in athymic nude mice, suggesting that its activity is T cell independent[3]. RDC Antibody Chimeric Human IgG1 kappa Human IgG1 kappa, Isotype Control \| \| \| \| \| \| \| \| \| \| [1]. Kamburova EG, et al. In vitro effects of rituximab on the proliferation, activation and differentiation of human B cells. Am J Transplant. 2012 Feb 12(2):341-50. [Content Brief] [2]. Manches O, et al. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood. 2003 Feb 1 101(3):949-54. [Content Brief] [3]. Byrd JC, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002 Feb 1 99(3):1038-43. [Content Brief]
Last Update	2025-04-01 14:45:47

MedChemExpress (MCE) also provides

Depatuxizumab

Category: Inhibitory Antibodies
CAS: 1471999-69-5
Last Update: 2025-04-01 14:45:47

Raxibacumab

Category: Inhibitory Antibodies
CAS: 565451-13-0
Last Update: 2025-04-01 14:45:47

Crizanlizumab

Category: Inhibitory Antibodies
CAS: 1690318-25-2
Last Update: 2025-04-01 14:45:47

Sofituzumab vedotin

Category: Inhibitory Antibodies
CAS: 1418200-58-4
Last Update: 2025-04-01 14:45:47

Fazpilodemab

Category: Inhibitory Antibodies
CAS: 2517935-02-1
Last Update: 2025-04-01 14:45:47

Osemitamab

Category: Inhibitory Antibodies
CAS: 2460539-61-9
Last Update: 2025-04-01 14:45:47

Visugromab

Category: Inhibitory Antibodies
CAS: 2556646-63-8
Last Update: 2025-04-01 14:45:47

Vobramitamab

Category: Inhibitory Antibodies
CAS: 2490556-50-6
Last Update: 2025-04-01 14:45:47


Supplier Name	MedChemExpress (MCE)
Contact	sales
Tel	609-228-6898
Mobile	609-228-6898
QQ
Email	sales@medchemexpress.com; tech@medchemexpress.com
Website	https://www.medchemexpress.com/
Wechat

Request for quotation

Supplier Contact